Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Paracrine growth factors are a broad class of secreted proteins that facilitate local cell-to-cell communication, regulating essential cellular activities such as growth, proliferation, and differentiation within the immediate tissue microenvironment. Unlike endocrine hormones that travel through the circulatory system, these factors act on adjacent target cells by binding to specific high-affinity receptors, often initiating receptor tyrosine kinase signaling cascades. They play a fundamental role in physiological processes including embryonic development, angiogenesis, and tissue regeneration (Source: Molecular Biology of the Cell, 4th edition; NIH). In various pathologies, the dysregulation of paracrine growth factors is a key driver of disease progression. For example, the overproduction of Vascular Endothelial Growth Factor (VEGF) is a hallmark of tumor-induced angiogenesis and wet age-related macular degeneration, while aberrant Fibroblast Growth Factor (FGF) or Platelet-Derived Growth Factor (PDGF) signaling is frequently implicated in tissue fibrosis and oncogenesis. Therapeutic interventions often involve monoclonal antibodies that sequester these ligands or small molecules that inhibit their respective receptors. While effective in treating cancer and vascular diseases, these therapies can lead to significant side effects such as hypertension and impaired wound healing due to the inhibition of normal physiological maintenance (Source: PubMed, StatPearls).
Drugs targeting paracrine growth factors typically function by neutralizing the secreted ligands through monoclonal antibodies or decoy receptors, thereby preventing them from binding to their cognate cell-surface receptors. Alternatively, small molecule inhibitors target the intracellular tyrosine kinase domains of the receptors activated by these factors to block downstream signaling pathways such as MAPK/ERK and PI3K/AKT (Source: NIH, StatPearls).
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Paracrine growth factors.